Publications

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

8 November 2023

NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently needed antibiotics.

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

2 November 2023

New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing compensation regardless of sales volume.

Reimagining Prevention for a Healthier, More Prosperous Society

12 October 2023

In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary measures, can help to reduce ill health, improve healthcare capacity, and increase wider economic growth.

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

18 September 2023

In this report, we explore the potential impact of the National Institute of Health and Care Excellence (NICE) decision outcomes on healthcare decision-making in 12 countries across the globe (Australia, Brazil, Canada, France, Italy, Israel, Japan, South Korea, Poland, Saudi Arabia, Sweden, and the United Arab Emirates). We used quantitative and qualitative methods to estimate the level of impact and potential underlying mechanisms.

Are Recommendations for HTA of Gene Therapies Being Achieved?

11 September 2023

In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

18 July 2023

The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS and wider society. The foreword has been provided by Angela Gibbons, patient and HS advocate.

This project has been organised and funded by Novartis Pharmaceuticals UK Ltd, with support from M+F Health. The report is informed by input from experts working in HS, including leading clinicians.

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

11 July 2023

This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted by dementia, and the economic benefits arising from dementia research in the UK.

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

19 May 2023

In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours.

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

15 May 2023

In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions.